Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
June 03, 2020 at 12:50 PM EDT
Geoffrey Porges upgraded Gilead Sciences from Market Perform to Outperform and raised the price target from $85 to $94.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|